Effect of food on the relative bioavailability of two oral formulations of posaconazole in healthy adults

British Journal of Clinical Pharmacology

Volumn 57, Issue 2, 2004, Pages 218-222

  Courtney, Rachel ^a   Wexler, David ^a   Radwanski, Elaine ^a   Lim, Josephine ^a   Laughlin, Mark ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Biological availability; Food effects; Pharmacokinetics; Posaconazole

Indexed keywords

FAT; POSACONAZOLE;

ADULT; ADULTHOOD; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIET RESTRICTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG EXPOSURE; DRUG FORMULATION; EVALUATION; FATIGUE; FOOD; GINGIVITIS; HEADACHE; HEALTH STATUS; HUMAN; LIPID DIET; MALE; MEAL; NORMAL HUMAN; OPEN STUDY; PRECIPITATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SINGLE DRUG DOSE; STATISTICAL SIGNIFICANCE; SUSPENSION; TABLET; TIME;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; ANTIBIOTICS, ANTIFUNGAL; BIOLOGICAL AVAILABILITY; CROSS-OVER STUDIES; FOOD; FOOD-DRUG INTERACTIONS; HUMANS; MALE; MIDDLE AGED; TABLETS; TRIAZOLES;

EID: 1242351713     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2125.2003.01977.x     Document Type: Article

References (16)

1. Pfaller MA, Jones RN, Messer SA, Edmond MB, Wenzel RP. National surveillance of nosocomial blood stream infection due to species of Candida other than Candida albicans: frequency of occurrence and antifungal susceptibility in the SCOPE program. SCOPE participant group. Surveillance and control of pathogens of epidemiologic. Diagn Microbiol Infect Dis 1998; 30: 121-9.
2. Barchiesi F, Schimizzi AM, Caselli F, et al. Activity of the new antifungal triazole, posaconazole, against Cryptococcus neoformans. J Antimicrob Chemother 2001; 48: 769-73.
3. Gonzalez GM, Tijerina R, Najvar LK, et al. In vitro and in vivo activities of posaconazole against Coccidioides immitis. Antimicrob Agents Chemother 2002; 46: 1352-6.
4. Sun QN, Fothergill AW, McCarthy DI, Rinaldi MG, Graybill JR. In vitro activities of posaconazole, itraconazole, voriconazole, amphotericin B, and fluconazole against 37 clinical isolates of zygomycetes. Antimicrob Agents Chemother 2002; 46: 1581-2.
5. Meletiadis J, Meis JF, Mouton JW, Rodriquez-Tudela JL, Donnelly JP, Verweij PE. In vitro activities of new and conventional antifungal agents against clinical Scedosporium isolates. Antimicrob Agents Chemother 2002; 46: 62-8.
6. Pfaller MA, Messer SA, Hollis RJ, Jones RN. In vitro activities of posaconazole (Sch 56592) compared with those of itraconazole and fluconazole against 3,685 clinical isolates of Candida spp. and Cryptococcus neoformans. Antimicrob Agents Chemother 2001; 45: 2862-4.
7. Manavathu EK, Cutright JL, Loebenberg D, Chandrasekar PH. A comparative study of the in vitro susceptibilities of clinical and laboratory-selected resistant isolates of Aspergillus spp. to amphotericin B, itraconazole, voriconazole and posaconazole (SCH 56592). J Antimicrob Chemother 2000; 46: 229-34.
8. Carrillo AJ, Guarro J. In vitro activities of four novel triazoles against Scedosporium spp. Antimicrob Agents Chemother 2001; 45: 2151-3.
9. Hachem RY, Raad II, Afif CM, et al. An open, non-comparative multicenter study to evaluate efficacy and safety of posaconazole (SCH 56592) in the treatment of invasive fungal infections (IFI) refractory (R) to or intolerant (I) to standard therapy (ST). Presented at Interscience Conference on Antimicrobial Agents and Chemotherapy; September 17-20, 2000: Toronto, Ontario, CAN. 372.
10. VFEND (voriconazole) [package insert]. New York, NY: Pfizer Inc 2002.
11. Zimmermann T, Yeates RA, Laufen H, Pfaff G, Wildfeuer A. Influence of concomitant food intake on the oral absorption of two triazole antifungal agents, itraconazole and fluconazole. Eur J Clin Pharmacol 1994; 46: 147-50.
12. Barone JA, Koh JG, Bierman RH, et al. Food interaction and steady-state pharmacokinetics of itraconazole capsules in healthy male volunteers. Antimicrob Agents Chemother 1993; 37: 778-84.
13. Singh BN. Effects of food on clinical pharmacokinetics. Clin Pharmacokinet 1999; 37: 213-55.
14. Courtney R, Pai S, Laughlin M, Lim J, Batra V. Pharmacokinetics, safety, and tolerability of oral posaconazole following single-and multiple-dose administration in healthy adult volunteers. Antimicrob Agents Chemother 2003; 41: 2788-95.
15. Gibaldi M, Perrier D. Pharmacokinetics, 2nd edn. New York: Marcel Dekker, 1982.
16. Hoffman HL, Ernst EJ, Klepser ME. Novel triazole antifungal agents. Exp Opin Invest Drugs 2000; 9: 593-605.